立体定向体部消融放疗再照射小体积头颈癌与延长生存相关:大型单机构现代队列研究
中位总生存期为44.3个月,中位SBRT剂量45 Gy,中位靶体积16.9 cc。全身治疗改善了非转移患者的区域控制(p=0.004)和远处控制(p=0.04);3级以上毒性在黏膜部位(p=0.001)和同步全身治疗(p=0.02)时更常见。
要点
- SBRT再照射小体积复发头颈癌的中位总生存期达44.3个月。
- 全身治疗可改善非转移患者的区域和远处控制。
- 黏膜部位照射和同步全身治疗增加3级以上毒性风险。
核心结论
- 对于复发小体积头颈癌,SBRT再照射可获得44.3个月的中位总生存期。
- 全身治疗改善非转移患者的区域和远处控制。
- 毒性受解剖部位和全身治疗影响。
研究设计与样本
- 分析失败模式、总生存期和毒性。
主要发现
- 中位总生存期为44.3个月。
- 中位SBRT剂量为45 Gy,中位靶体积为16.9 cc。
- 1年局部、区域和远处控制率分别为78%、66%和83%。
- 全身治疗改善非转移患者的区域控制(p=0.004)和远处控制(p=0.04)。
- 3级以上毒性在黏膜部位(p=0.001)和同步全身治疗(p=0.02)时更常见。
临床怎么用
- SBRT再照射可作为小体积复发头颈癌的根治性治疗选择,需关注黏膜部位和同步全身治疗相关的毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent head and neck cancer has poor prognosis. Stereotactic body radiotherapy (SBRT) may improve outcomes by delivering ablative radiation doses. METHODS: We reviewed patients who received definitive-intent SBRT reirradiation at our institution from 2013 to 2020. Patterns of failure, overall survival (OS), and toxicities were analyzed. RESULTS: One hundred and thirty-seven patients were evaluated. The median OS was 44.3 months. The median SBRT dose was 45 Gy and median target volume 16.9 cc. The 1-year local, regional, and distant control was 78%, 66%, and 83%, respectively. Systemic therapy improved regional (p = 0.004) and distant control (p = 0.04) in nonmetastatic patients. Grade 3+ toxicities were more common at mucosal sites (p = 0.001) and with concurrent systemic therapy (p = 0.02). CONCLUSIONS: In a large cohort of SBRT reirradiation for recurrent, small volume head and neck cancers, a median OS of 44.3 months was observed. Systemic therapy improved regional and distant control. Toxicities were modulated by anatomic site and systemic therapy.
引用
- Diao K, Nguyen TP, Moreno AC, et al. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021. PMID: 34269492. doi:10.1002/hed.26820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。